Discussion of the Group’s management structures and corporate governance procedures is set out in Corporate governance.

Discussion of the Group’s operating and financial performance and financial resources is given in the Operating and financial review and prospects.

In this report: ‘GlaxoSmithKline’ or the ‘Group’ means GlaxoSmithKline plc and its subsidiary and associated undertakings and the ‘company’ means GlaxoSmithKline plc; ‘GlaxoSmithKline share’ means an Ordinary Share of GlaxoSmithKline plc of 25p.

Throughout this report, figures quoted for market size, market share and market growth rates relate to the year ended 30th September 2000 (or later where available). These are GlaxoSmithKline estimates based on the most recent data from independent external sources, valued in sterling at relevant exchange rates. Figures quoted for product market share reflect sales by GlaxoSmithKline and licensees.

Brand names appearing in italics throughout this report are trade marks of GlaxoSmithKline plc, its subsidiaries or associated companies, with the exception of Nicoderm, a trade mark of Hoechst Marion Roussel Inc; Bexxar, a trade mark of Corixa Corporation, Inc; Coreg, a trade mark under licence from Roche Laboratories, Inc; Factive, a trade mark of LG Chemical, Ltd; Navelbine, a trade mark of Pierre Fabré Médicament and Panorex, a trade mark of Centocor, Inc, all of which are used under licence by the Group.